The FDA issued a non-approvable letter for the long-acting injectable version of Zyprexa due to concerns over excessive sedation. That won't do much to stem Zyprexa's hemorrhaging market share. Guess that's just a little less milk for this cash cow.
Saturday, March 1, 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment